EU approves Fasenra for severe eosinophilic asthma

AstraZeneca and its global biologics research and development arm, MedImmune, have announced that the European Commission (EC) has approved Fasenra (benralizumab) as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists.

The approval is based on the results from the WINDWARD programme, including the pivotal Phase III exacerbation trials, SIROCCO and CALIMA, and the Phase III OCS-sparing trial, ZONDA.

Eosinophils are a type of white blood cell that are a normal part of the body's immune system. Elevated levels of eosinophils, seen in around half of severe asthma patients, impact airway inflammation and airway hyper-responsiveness, resulting in increased asthma severity and symptoms, decreased lung function and increased risk of exacerbations.

Fasenra binds directly to the IL-5α receptor on an eosinophil and attracts natural killer cells to induce apoptosis (programmed cell death).

Fasenra will be available as a fixed-dose subcutaneous injection via a prefilled syringe administered once every four weeks for the first three doses, and then once every eight weeks thereafter.

In November 2017 the US Food and Drug Administration approved Fasenra for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Tim Harrison, Professor of Asthma and Respiratory Medicine, University of Nottingham, and investigator in the WINDWARD trial programme, said: “Many patients with severe eosinophilic asthma experience debilitating symptoms and face increased risk of emergency room visits, hospitalisations and death, despite current treatments. I look forward to being able to offer Fasenra as a new anti-eosinophilic monoclonal antibody which has demonstrated efficacy versus placebo in pivotal clinical trials and has the convenience of an 8-week maintenance dosing regimen.”

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “[This] decision from the EC follows the recent approval of Fasenra in the US and is another positive step towards our ambition to transform care for severe asthma patients whose disease is driven by eosinophilic inflammation.”

Fasenra is also under regulatory review in Japan and several other countries, with expected regulatory decisions in H1 2018.

 

Make a comment

To voice your opinion, please Log in or Register.

Recent comments (1)

  • Elizabeth Millazo

    I had chronic obstructive pulmonary disease (COPD) for 15 years. My first symptoms were dry cough, chest tightness and shortness of breath. My first chest x-ray only showed bronchitis. Finally I went to a pulmonologist, After many tests it was a CT scan that showed COPD, and scarring in my lungs. I quit smoking 17 years and 6 months ago. But the damage has been done. I got to the point I couldn't catch my breath and was coughing so hard I thought the top of my head would blow off. The day after I had the scan I was on oxygen the next night and was on it 24/7. December 2017 my pulmonologist and I decided to go with natural treatment and was introduced to Mbeki Herbal Clinic natural organic COPD Herbal formula, i had a total decline of symptoms with this COPD Herbal formula treatment. The infections, shortness of breath, fatigue, dry cough and other symptoms has subsided. Visit Mbeki Herbal Clinic official website ww w. mbekiherbalclinic. com or email herbs@ mbekiherbalclinic. com. I have had great improvement with my over all respiration with this product and i breath very much easier, i can never be thankful enough to nature